Sight Sciences (NASDAQ:SGHT) CTO Sells $28,424.64 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 8,168 shares of Sight Sciences stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.48, for a total transaction of $28,424.64. Following the transaction, the chief technology officer directly owned 1,990,290 shares in the company, valued at $6,926,209.20. This represents a 0.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

David Badawi also recently made the following trade(s):

• On Friday, January 16th, David Badawi sold 4,836 shares of Sight Sciences stock. The stock was sold at an average price of $6.62, for a total transaction of $32,014.32.
• On Tuesday, January 6th, David Badawi sold 3,695 shares of Sight Sciences stock. The stock was sold at an average price of $7.48, for a total transaction of $27,638.60.
• On Monday, January 5th, David Badawi sold 3,051 shares of Sight Sciences stock. The shares were sold at an average price of $7.82, for a total transaction of $23,858.82.

Sight Sciences Price Performance

SGHT opened at $3.52 on Monday. The stock has a market cap of $190.12 million, a price-to-earnings ratio of -4.69 and a beta of 2.50. The company has a debt-to-equity ratio of 0.63, a quick ratio of 9.52 and a current ratio of 10.22. The firm’s fifty day moving average is $4.82 and its 200 day moving average is $5.76. Sight Sciences, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $9.24.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Wednesday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.07. Sight Sciences had a negative return on equity of 55.72% and a negative net margin of 49.67%.The business had revenue of $20.39 million during the quarter, compared to analyst estimates of $20.35 million. On average, sell-side analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on SGHT. Piper Sandler set a $9.00 price target on Sight Sciences in a report on Monday, January 5th. Cantor Fitzgerald set a $8.00 price objective on shares of Sight Sciences in a research report on Monday, March 2nd. William Blair reissued an “outperform” rating on shares of Sight Sciences in a report on Thursday, March 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research report on Monday, December 29th. Finally, Citigroup cut their target price on shares of Sight Sciences from $9.10 to $6.50 and set a “neutral” rating for the company in a research note on Friday, March 6th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Sight Sciences currently has an average rating of “Hold” and an average price target of $8.31.

Institutional Investors Weigh In On Sight Sciences

Several institutional investors have recently made changes to their positions in SGHT. BNP Paribas Financial Markets grew its holdings in Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock valued at $26,000 after purchasing an additional 3,785 shares during the last quarter. O Shaughnessy Asset Management LLC purchased a new stake in Sight Sciences in the 4th quarter worth about $81,000. AXQ Capital LP bought a new stake in Sight Sciences in the fourth quarter worth about $89,000. Tower Research Capital LLC TRC boosted its position in shares of Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after buying an additional 2,875 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Sight Sciences during the fourth quarter valued at approximately $96,000. Institutional investors own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.